---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269525"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:39:52.187136+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences Q3 revenue $19.9M, raises FY25 guidance; promotes COO and CFO

## Summary
- Surgical Glaucoma revenue $19.7M (+6% YoY); Dry Eye revenue $0.2M (-88%) as company focuses on reimbursed access.
- Net loss narrowed to $8.2M ($0.16 loss per share) from $11.1M loss in Q3 2024.
- Raises FY2025 revenue guidance to $76-78M (from $72-76M); reduces adj. op. expense guidance to $90-92M.
- Promoted Alison Bauerlein to COO from CFO, James Rodberg to CFO, effective Nov 5, 2025.
- Board members Becker and Rogers resigned; board size reduced from 9 to 7.

## SEC filing metadata
- accession: 0001193125-25-269525
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000119312525269525/0001193125-25-269525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000119312525269525/sght-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269525
- JSON: https://secwatch.observer/filing/0001193125-25-269525.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.